GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

I was prescribed the drugs tambulosin and finasteride for an enlarged prostate. But I was never warned that they might make ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Despite its profile as a long-acting IL-5 receptor antagonist with convenient semiannual dosing, GSK's depemokimab, the most advanced asthma pipeline asset, has generated relatively limited ...

Two of the treatments that will be receiving plenty of attention in GSK’s presentations are mepolizumab and depemokimab, which are both monoclonal antibodies (mAbs) that target IL-5, a key cytokine or ...

These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK plc (NYSE:GSK) ranks first among the 8 most undervalued healthcare stocks to buy according to analysts.

Please provide your email address to receive an email when new articles are posted on . Depemokimab’s mechanism of action is similar to mepolizumab. Three adverse events led to discontinuation ...

04 November 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June ...

Also Read: GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review ICER President and CEO Sarah K. Emond emphasized the significance of the report, highlighting that over 15 ...

GSK plc announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications. The proposed indications are as add ...